Ginkgo Bioworks Holdings (DNA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Ginkgo Bioworks Holdings (DNA) has a cash flow conversion efficiency ratio of -0.105x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-46.43 Million) by net assets ($443.15 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Ginkgo Bioworks Holdings liquidity coverage in days to measure how many days the company can operate on defensive assets alone.
Ginkgo Bioworks Holdings - Cash Flow Conversion Efficiency Trend (2019–2025)
This chart illustrates how Ginkgo Bioworks Holdings's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Ginkgo Bioworks Holdings Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Ginkgo Bioworks Holdings ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Shenzhen Longli Technology Co Ltd Class A
SHE:300752
|
0.018x |
|
Songz Automobile Air Conditioning Co Ltd
SHE:002454
|
0.014x |
|
Guangzhou Boji Medical and Biotechnological Co Ltd
SHE:300404
|
-0.007x |
|
Nanjing Well Pharmaceutical Co Ltd
SHG:603351
|
0.039x |
|
Irish Residential Properties
IR:IRES
|
0.019x |
|
First Foundation Inc.
NYSE:FFWM
|
-0.027x |
|
Stitch Fix
NASDAQ:SFIX
|
0.058x |
|
Zinzino AB Series B
ST:ZZ-B
|
0.384x |
Annual Cash Flow Conversion Efficiency for Ginkgo Bioworks Holdings (2019–2025)
The table below shows the annual cash flow conversion efficiency of Ginkgo Bioworks Holdings from 2019 to 2025. For the full company profile with market capitalisation and key ratios, see market cap of Ginkgo Bioworks Holdings.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $508.59 Million | $-171.06 Million | -0.336x | +24.64% |
| 2024-12-31 | $716.06 Million | $-319.58 Million | -0.446x | -65.71% |
| 2023-12-31 | $1.10 Billion | $-295.50 Million | -0.269x | -85.42% |
| 2022-12-31 | $1.74 Billion | $-252.20 Million | -0.145x | +10.30% |
| 2021-12-31 | $1.57 Billion | $-253.82 Million | -0.162x | +43.96% |
| 2020-12-31 | $470.05 Million | $-135.83 Million | -0.289x | -224.70% |
| 2019-12-31 | $501.85 Million | $-44.66 Million | -0.089x | -- |
About Ginkgo Bioworks Holdings
Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops a platform for cell engineering in the United States. It operates through the Cell Engineering and Biosecurity segments. The company offers cell engineering research and development solutions, as well as cell engineering tools comprising functional genomics, antibody developability, and small molecule developability, artific… Read more